Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIMISE: Optimized Immunosuppression for Corneal Transplantation
2022-500109-41-00Phase 4Authorised
- Sponsor
- Maastricht University Medical Center+
- Start
- Jun 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 4, randomised trial in corneal endothelial disease (CED) and Keratoplasty comparing Fluorometholone regimen with Dexamethasone regimen (2 arms). Primary endpoints: Intraocular pressure elevation in year 1 and Endothelial cell loss in year 2. Planned start Jun 2022; status: authorised.
02
Drugs
fluorometholonedexamethasone
03
Conditions
corneal endothelial disease (CED)Keratoplasty
Beyond the preview
Go deeper on 2022-500109-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500109-41-00.